Brian Park, PharmD

Drug Information Specialist https://www.dermatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Practice Management

FDA: Remdesivir is Effective for COVID-19 Treatment Despite WHO Study

Brian Park, PharmD

December 2, 2020

The FDA stated that results from the SOLIDARITY trial did not refute the findings of clinical benefit for remdesivir.

Psoriasis

Synovitis Reduction Observed With Secukinumab in Psoriatic Arthritis Trial

Brian Park, PharmD

November 11, 2020

The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.

Psoriasis

Deucravacitinib Shows Superiority to Apremilast in Psoriasis Trial

Brian Park, PharmD

November 10, 2020

A phase 3 trial evaluating the efficacy and safety of deucravacitinib (BMS-986165; Bristol Myers Squibb), a novel, oral, selective TYK2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis met both co-primary and secondary end points.

Practice Management

Antibody Cocktail for COVID-19 Cuts Viral Load, Medical Visits

Brian Park, PharmD

November 4, 2020

REGN-COV2 consists of 2 virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.

General Dermatology

FDA Approves Rx-to-OTC Switch of Sklice for Head Lice Treatment

Brian Park, PharmD

November 3, 2020

Each gram of lotion contains 5mg of ivermectin, the same as the prescription strength.

Dermatitis

Topical Live Biotherapeutic Gets Fast Track Status for Atopic Dermatitis

Brian Park, PharmD

October 28, 2020

FB-401 is a topically applied live biotherapeutic that consists of 3 therapeutic strains of commensal Roseomonas mucosa.

Practice Management

FDA Approves Veklury as First Treatment for COVID-19

Brian Park, PharmD

October 27, 2020

The FDA approved Veklury (remdesivir; Gilead Sciences) for the treatment of COVID-19 in patients aged ≥12 years (weighing ≥40kg) requiring hospitalization.

Dermatitis

AbbVie Seeks Approval of Upadacitinib for Atopic Dermatitis

Brian Park, PharmD

October 23, 2020

The regulatory application is supported by data from 3 randomized, double-blind, placebo-controlled phase 3 studies.

Practice Management

NIH: Immune Modulators to Be Investigated for COVID-19

Brian Park, PharmD

October 23, 2020

The NIH-led trial will assess 3 drugs: infliximab, a tumor necrosis factor blocker, abatacept, a selective T cell costimulation modulator, and cenicriviroc, an investigational immunomodulator that blocks 2 chemokine receptors, CCR2 and CCR5.

Practice Management

Remdesivir Distribution Transitioned to Gilead Under Revised EUA

Brian Park, PharmD

October 8, 2020

By increasing manufacturing capacity, Gilead has been able to expand the supply of remdesivir, which now exceeds market demand.

Next post in Practice Management